Sandy Kuo, MD; Karen E. Huang, MS; Scott A. Davis, MA; Steven R. Feldman, MD, PhD
From the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences.
The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. Dr. Kuo, Ms. Huang, and Mr. Davis report no conflict of interest. Dr. Feldman is a speaker for Janssen Biotech, Inc, and Taro Pharmaceuticals USA, Inc, and a consultant for Amgen Inc; Baxter; HanAll BioPharma Co, Ltd; Kikaku America International; Merck & Co, Inc; Merz Inc; Mylan Inc; Novartis Corporation; Pfizer Inc; and XenoPort, Inc. He also is a consultant and speaker for Abbott Laboratories; Eli Lilly and Company; Galderma Laboratories, LP; LEO Pharma; and Stiefel, a GSK company. Dr. Feldman also has received grants from Abbott Laboratories; Amgen Inc; Anacor Pharmaceuticals, Inc; Celgene Corporation; Galderma Laboratories, LP; Janssen Biotech, Inc; and Stiefel, a GSK company. He also is on the advisory board for Pfizer Inc, and is a founder and stockholder for Causa Research.
Correspondence: Karen E. Huang, MS, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (kehuang@wakehealth.edu).
The rosacea patient journey model progresses from development of disease and diagnosis to treatment and disease management. Download the PDF of the authors' model for future reference. To access the full article, click here.
